BIOMAT Database Logo BIOMAT Database Logo

[Selective thrombolysis with recombinant tissue type plasminogen activator in combination with prostaglandin E1]. 1989

H Bertuch, and E Pilger, and G Stark, and J Lammer

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D007511 Ischemia A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION. Ischemias
D007866 Leg The inferior part of the lower extremity between the KNEE and the ANKLE. Legs
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000527 Alprostadil A potent vasodilator agent that increases peripheral blood flow. PGE1,Prostaglandin E1,Caverject,Edex,Lipo-PGE1,Minprog,Muse,PGE1alpha,Prostaglandin E1alpha,Prostavasin,Prostin VR,Prostine VR,Sugiran,Vasaprostan,Viridal,Lipo PGE1
D001157 Arterial Occlusive Diseases Pathological processes which result in the partial or complete obstruction of ARTERIES. They are characterized by greatly reduced or absence of blood flow through these vessels. They are also known as arterial insufficiency. Arterial Obstructive Diseases,Arterial Occlusion,Arterial Obstructive Disease,Arterial Occlusions,Arterial Occlusive Disease,Disease, Arterial Obstructive,Disease, Arterial Occlusive,Obstructive Disease, Arterial,Occlusion, Arterial,Occlusive Disease, Arterial

Related Publications

H Bertuch, and E Pilger, and G Stark, and J Lammer
Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
October 1984, Circulation,
H Bertuch, and E Pilger, and G Stark, and J Lammer
Clot-selective coronary thrombolysis with tissue-type plasminogen activator.
June 1983, Science (New York, N.Y.),
H Bertuch, and E Pilger, and G Stark, and J Lammer
Renal artery embolism: thrombolysis with recombinant tissue-type plasminogen activator.
September 1990, Journal of internal medicine,
H Bertuch, and E Pilger, and G Stark, and J Lammer
Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator?
April 1990, Annals of internal medicine,
H Bertuch, and E Pilger, and G Stark, and J Lammer
Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits.
August 1985, Blood,
H Bertuch, and E Pilger, and G Stark, and J Lammer
Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator.
April 1992, Journal of the American College of Cardiology,
H Bertuch, and E Pilger, and G Stark, and J Lammer
[Thrombolysis in acute ischemic stroke with intravenous recombinant tissue-type plasminogen activator].
November 2002, Orvosi hetilap,
H Bertuch, and E Pilger, and G Stark, and J Lammer
Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis.
March 1993, Radiology,
H Bertuch, and E Pilger, and G Stark, and J Lammer
Thrombolysis with recombinant tissue plasminogen activator in 7 children.
September 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis,
H Bertuch, and E Pilger, and G Stark, and J Lammer
Coronary thrombolysis with tissue-type plasminogen activator.
February 1987, Cardiology clinics,
Copied contents to your clipboard!